Elexacaftor CAS# 2216712-66-0
Elexacaftor, also known as VX-445 and WHO 11180, is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function in patients with cystic fibrosis when administered with tezacaftor and ivacaftor (VX-445–tezacaftor–ivacaftor).
📌 参考资料/链接：
Haseltine, Eric L.; Moskowitz, Samuel; Robertson, Sarah; Waltz, David. Methods of treatment for cystic fibrosis. Assignee Vertex Pharmaceuticals Incorporated, USA. WO 2019018395. (2019).
Haseltine, Eric L.; Moskowitz, Samuel; Robertson, Sarah; Waltz, David. Methods of treatment for cystic fibrosis. Assignee Vertex Pharmaceuticals Incorporated, USA. WO 2019018395. (2019).
📄 详细内容
CAS No. 2216712-66-0 Elexacaftor synthetic routes
Haseltine, Eric L.; Moskowitz, Samuel; Robertson, Sarah; Waltz, David. Methods of treatment for cystic fibrosis. Assignee Vertex Pharmaceuticals Incorporated, USA. WO 2019018395. (2019).
产品链接: CAS No. 2216712-66-0 ››
Haseltine, Eric L.; Moskowitz, Samuel; Robertson, Sarah; Waltz, David. Methods of treatment for cystic fibrosis. Assignee Vertex Pharmaceuticals Incorporated, USA. WO 2019018395. (2019).
产品链接: CAS No. 2216712-66-0 ››